Removing Myeloid Inhibitory Signals to Enable Anti-Tumor Response & Restore Immune Activity

Time: 9:30 am
day: Day Two


• Charting signaling, inhibitory, and excitatory pathways of myeloid cell populations to identify novel cascades of therapeutic value

• Sharing lessons learned from MCSF receptor inhibition in the clinic to modulate MDSCs and macrophages

• Developing TIM3 therapies as a checkpoint for both myeloid and T cells, and discussing the mechanism of action and therapeutic rationale